Literature DB >> 26755207

Implantable cardioverter-defibrillator elective generator replacement: a procedure for all?

Sergio Barra1, Manoj Goonewardene2,3, Patrick Heck2, David Begley2, Munmohan Virdee2, Simon Fynn2, Andrew Grace2, Sharad Agarwal2.   

Abstract

PURPOSE: Six risk stratification scores have been developed to estimate mortality risk in patients receiving an implantable cardioverter-defibrillator (ICD). This study aims at validating and comparing these risk scores in patients having elective ICD generator replacement (GR) and assessing the outcome of patients submitted to this procedure.
METHODS: Two hundred twenty three consecutive patients with ischaemic or non-ischaemic dilated cardiomyopathy submitted to elective ICD GR and followed-up for 44 ± 19 months were included. We evaluated which of six previously developed risk scores could predict post-discharge all-cause mortality risk in this context with the highest efficacy. Comparisons between these scores were made using receiver-operating characteristic curves and the integrated discrimination improvement (IDI) index. We further assessed risk of appropriate ICD therapies and all-cause mortality following ICD GR.
RESULTS: The prognostic utility of the six scores was assessed by calculating the AUC for follow-up all-cause mortality prediction: Goldenberg - 0.758 ± 0.042, p < 0.001; Parkash - 0.754 ± 0.042, p < 0.001; Bilchick - 0.813 ± 0.038, p < 0.001; Kraaier - 0.721 ± 0.043, p < 0.001; REPLACE DARE - 0.746 ± 0.048, p < 0.001; Providencia - 0.739 ± 0.043, p < 0.001. Through measures of risk reclassification (IDI and relative IDI), the score by Bilchick et al. was shown to outperform all other scores. Binary logistic regression identified pre-GR-appropriate ICD therapy as an independent predictor of post-GR ICD therapy (OR 6.2, CI 95% 3.0-12.7, p < 0.001), along with male gender (OR 6.6, CI 95% 0.8-55, p = 0.082) and history of atrial fibrillation (OR 2.28, CI 95% 1.1-4.5, p = 0.019).
CONCLUSIONS: Current prediction scores are useful in predicting mortality risk of patients considered for ICD generator replacement and can potentially help identify patients who may not benefit from continuous ICD treatment due to high mortality rates regardless of the ICD.

Entities:  

Keywords:  All-cause mortality; Generator replacement; ICD therapy; Implantable cardioverter-defibrillator; Risk stratification

Mesh:

Year:  2016        PMID: 26755207     DOI: 10.1007/s10840-015-0087-0

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  23 in total

1.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH).

Authors:  K H Kuck; R Cappato; J Siebels; R Rüppel
Journal:  Circulation       Date:  2000-08-15       Impact factor: 29.690

2.  Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.

Authors:  Ilan Goldenberg; Anant K Vyas; W Jackson Hall; Arthur J Moss; Hongyue Wang; Hua He; Wojciech Zareba; Scott McNitt; Mark L Andrews
Journal:  J Am Coll Cardiol       Date:  2008-01-22       Impact factor: 24.094

3.  Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score.

Authors:  Karin Kraaier; Marcoen F Scholten; Jan G P Tijssen; Dominic A M J Theuns; Luc J L M Jordaens; Arthur A M Wilde; Pascal F H M van Dessel
Journal:  Europace       Date:  2013-08-04       Impact factor: 5.214

4.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

5.  Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients.

Authors:  Guido H van Welsenes; Johannes B van Rees; C Jan Willem Borleffs; Suzanne C Cannegieter; Jeroen J Bax; Lieselot van Erven; Martin J Schalij
Journal:  Europace       Date:  2011-01-05       Impact factor: 5.214

6.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

7.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

8.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; D Roy; R S Sheldon; L B Mitchell; M S Green; G J Klein; B O'Brien
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

9.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

10.  REPLACE DARE (Death After Replacement Evaluation) score: determinants of all-cause mortality after implantable device replacement or upgrade from the REPLACE registry.

Authors:  Mina K Chung; Richard G Holcomb; Suneet Mittal; Jonathan S Steinberg; Marye J Gleva; Theofanie Mela; Daniel Z Uslan; Kevin Mitchell; Jeanne E Poole
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.